Alzamend Neuro, Inc.
ALZN · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.04 | 1.76 | -0.15 |
| FCF Yield | -256.49% | -3.89% | -0.38% | -0.16% |
| EV / EBITDA | 0.29 | -21.87 | -156.65 | -330.36 |
| Quality | ||||
| ROIC | -113.32% | 433.32% | -488.26% | -92.27% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.45 | 0.83 | 0.60 | 0.54 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 18.40% | 5.67% | -32.78% | -147.80% |
| Safety | ||||
| Net Debt / EBITDA | 0.89 | 0.01 | 0.35 | 1.14 |
| Interest Coverage | -249.42 | -983.86 | -1,930.92 | -264.81 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,566.18 | 0.00 | 0.00 | 0.00 |